Neuland Laboratories share news, announcements and annual reports
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,315.00up ₹260.00 (1.36%)BSE ₹19,292.05
Share price at the NSE close on 27 Oct 2026. Previous close ₹19,055.00.
27 Oct: open ₹19,055.00, high ₹19,485.00, low ₹19,055.00
52-week range of traded prices to 27 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹24,781 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 49.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 22,94443.0% delivered
Neuland Laboratories has 836 announcements on record, routine notices left out; 2 in the 30 days to 28 Oct 2026, the latest on 22 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Neuland Laboratories quarterly results
Nov3Tue
The board meets on 3 Nov 2026 to consider financial results
Notice filed 22 Oct 2026
Neuland Laboratories annual reports, presentations and earnings calls
The company's own documents, latest first.Neuland Laboratories financials, year by year
Annual reports16
- Annual report, year to Mar 20269 Jul 2026
- Annual report, year to Mar 20254 Jul 2025
- Annual report, year to Mar 20245 Jul 2024
- Annual report, year to Mar 20233 Jul 2023, a zip file
- Annual report, year to Mar 20227 Jul 2022, a zip file
11 earlier reports
- Annual report, year to Mar 202114 Jun 2021, a zip file
- Annual report, year to Mar 202025 Sep 2020, a zip file
- Annual report, year to Mar 201910 Jun 2019, a zip file
- Annual report, year to Mar 201810 Aug 2018, a zip file
- Annual report, year to Mar 201729 Dec 2017, a zip file
- Annual report, year to Mar 201622 Aug 2016, a zip file
- Annual report, year to Mar 201523 Jul 2015, a zip file
- Annual report, year to Mar 201430 May 2014, a zip file
- Annual report, year to Mar 20135 Jul 2013, a zip file
- Annual report, year to Mar 201220 Jul 2012, a zip file
- Annual report, year to Mar 20108 Aug 2011, a zip file
Investor presentations22
- Investor Presentation5 Aug 2026
- Investor Presentation12 May 2026
- Investor Presentation9 Feb 2026
- Investor Presentation7 Nov 2025
- Investor Presentation31 Jul 2025
17 earlier presentations
- Investor Presentation15 May 2025
- Investor Presentation10 Feb 2025
- Investor Presentation6 Nov 2024
- Investor Presentation1 Aug 2024
- Investor Presentation12 May 2024
- Investor Presentation10 May 2024
- Investor Presentation8 Feb 2024
- Investor Presentation7 Nov 2023
- Investor Presentation3 Aug 2023
- Investor Presentation11 May 2023
- Investor Presentation10 May 2022
- Investor Presentation1 Feb 2022
- Investor Presentation29 Oct 2021
- Investor Presentation3 Aug 2021
- Investor Presentation11 May 2021
- Investor Presentation2 Feb 2021
- Investor Presentation3 Nov 2020
Earnings calls35
- Transcript of the Earnings Call conducted on August 5, 202610 Aug 2026
- Audio Recording of the Earnings call conducted on August 5, 20265 Aug 2026
- Transcript of the Earnings Call conducted on May 12, 202616 May 2026
- Link of Recording12 May 2026
- Transcript13 Feb 2026
30 earlier call documents
- Link of Recording9 Feb 2026
- Transcript12 Nov 2025
- Audio Recording of the Earnings call conducted on November 7, 20257 Nov 2025
- Transcript4 Aug 2025
- Link of Recording31 Jul 2025
- Transcript19 May 2025
- Link of Recording15 May 2025
- Transcript14 Feb 2025
- Link of Recording11 Feb 2025
- Transcript12 Nov 2024
- Link of Recording6 Nov 2024
- Transcript6 Aug 2024
- Link of Recording1 Aug 2024
- Transcript17 May 2024
- Link of Recording14 May 2024
- Transcript13 Feb 2024
- Link of Recording9 Feb 2024
- Transcript13 Nov 2023
- Link of Recording7 Nov 2023
- Transcript8 Aug 2023
- Link of Recording3 Aug 2023
- Transcript16 May 2023
- Please find below the link of the audio recording of the Earnings call for the quarter and year ended March 31, 2023, conducted on May 11, 202311 May 2023
- Transcript17 Feb 2023
- Link of Recording14 Feb 2023
- Transcript of the Earnings call conducted on November 10, 202216 Nov 2022
- Audio Recording of the earnings call conducted on November 10, 202211 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call8 Aug 2022
- Audio Recordings Of The Earnings Call Conducted On August 3, 2022.3 Aug 2022
- In continuation to our intimation dated May 5, 2022, we would like to inform you that the audio recording and the transcript (attached) of the Earnings Call on Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022, held on May 10, 2022, have been uploaded on the website of the Company on May 10, 2022 and May 13, 2022 respectively. Please find below the weblinks to access the same:Web link to access audio recording is as under:https://www.neulandlabs.com/investors/investor-updates/investors-call-recordings/Web link to access above transcript is as under:https://www.neulandlabs.com/investors/investor-updates/announcements/This is for your information and records.31 May 2022
Neuland Laboratories merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings4
- Update on the Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited (Transferee Company) and Neuland Health Sciences Private Limited (First Transferor Company) and Neuland Pharma Research Private Limited (Second Transferor Company) and their respective Shareholders and Creditors16 Apr 2018, a zip file
- Update on the Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited (Transferee Company) and Neuland Health Sciences Private Limited (First Transferor Company) and Neuland Pharma Research Private Limited (Second Transferor Company) and their respective Shareholders and Creditors ("Scheme").28 Mar 2018, a zip file
- Tribunal Convened Meeting of the Trade Creditors of the Company ( TCM ) was held on June 10, 2017 . The Resolution pertaining to the Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited (Transferee Company) and Neuland Health Sciences Private Limited (First Transferor Company) and Neuland Pharma Research Private Limited (Second Transferor Company) and their respective Shareholders and Creditors, has been passed by the Trade Creditors of the Company with requisite majority.12 Jun 2017, a zip file
- Presentation on Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited ( NLL ) and Neuland Health Sciences Private Limited ( NHSPL ) and Neuland Pharma Research Private Limited ( NPRPL ) being uploaded on the Website of the Company.8 Nov 2016, a zip file
Neuland Laboratories share news and announcements
Newest first. Page 1 of 17.
Oct 2026
Sep 2026
15 Sep · Business
7 Sep · Updates
Aug 2026
25 Aug · Rating
14 Aug · Updates
7 Aug · Analysts
5 Aug · Results
Jul 2026
31 Jul · Updates
28 Jul · Analysts
20 Jul · Board meeting
13 Jul · Rating
Jun 2026
May 2026
22 May · Analysts
12 May · Results
Apr 2026
29 Apr · Analysts
1 Apr · Business
Mar 2026
3 Mar · Analysts
Feb 2026
11 Feb · Updates
4 Feb · Analysts
Jan 2026
27 Jan · Analysts
2 Jan · Updates
Dec 2025
8 Dec · Updates
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 26 Aug 2026Credit ratingup 2.60%+2.8 pts vs Nifty 500market median 0.0% · five sessions +0.3% (+1.5 pts vs Nifty 500) · volume 0.4× usual · delivery +7.3 pts against usual · The announcement
- 6 Aug 2026Resultsup 7.95%+8.0 pts vs Nifty 500market median −0.7% · five sessions +12.8% (+13.1 pts vs Nifty 500) · volume 27.0× usual · delivery −22.6 pts against usual · The announcement
- 14 Jul 2026Credit ratingdown 0.11%+0.5 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−0.3 pts vs Nifty 500) · volume 0.3× usual · delivery −4.5 pts against usual · The announcement
- 13 May 2026Resultsdown 2.98%−3.3 pts vs Nifty 500market median −0.7% · five sessions −1.3% (−2.2 pts vs Nifty 500) · volume 7.8× usual · delivery −13.1 pts against usual · The announcement
- 10 Feb 2026Resultsdown 2.79%−3.1 pts vs Nifty 500market median −0.7% · five sessions −4.6% (−3.7 pts vs Nifty 500) · volume 4.3× usual · delivery −8.8 pts against usual · The announcement
- 10 Nov 2025Resultsup 1.55%+1.2 pts vs Nifty 500market median −0.7% · five sessions −2.1% (−3.4 pts vs Nifty 500) · volume 10.2× usual · delivery −16.3 pts against usual · The announcement
- 1 Aug 2025Resultsdown 1.99%−0.9 pts vs Nifty 500market median −0.7% · five sessions −3.4% (−2.4 pts vs Nifty 500) · volume 1.9× usual · delivery +4.1 pts against usual · The announcement
- 23 Jun 2025Credit ratingup 0.51%+0.7 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−3.5 pts vs Nifty 500) · volume 0.4× usual · delivery −9.4 pts against usual · The announcement
- 16 May 2025Resultsdown 6.77%−7.1 pts vs Nifty 500market median −0.7% · five sessions −5.6% (−4.8 pts vs Nifty 500) · volume 6.8× usual · delivery +6.3 pts against usual · The announcement
- 16 May 2025Dividenddown 6.77%−7.1 pts vs Nifty 500market median 0.0% · five sessions −5.6% (−4.8 pts vs Nifty 500) · volume 6.8× usual · delivery +6.3 pts against usual · The announcement
20 earlier announcements
- 16 May 2025Board or managers changeddown 6.77%−7.1 pts vs Nifty 500market median 0.0% · five sessions −5.6% (−4.8 pts vs Nifty 500) · volume 6.8× usual · delivery +6.3 pts against usual · The announcement
- 10 Mar 2025Board or managers changeddown 5.72%−4.9 pts vs Nifty 500market median 0.0% · five sessions −10.7% (−10.0 pts vs Nifty 500) · volume 0.8× usual · delivery −4.9 pts against usual · The announcement
- 10 Mar 2025Credit ratingdown 5.72%−4.9 pts vs Nifty 500market median 0.0% · five sessions −10.7% (−10.0 pts vs Nifty 500) · volume 0.8× usual · delivery −4.9 pts against usual · The announcement
- 1 Feb 2025Board or managers changedup 0.50%+0.5 pts vs Nifty 500market median 0.0% · five sessions +2.6% (+2.1 pts vs Nifty 500) · volume 0.2× usual · delivery −19.4 pts against usual · The announcement
- 13 May 2024Dividenddown 15.11%−15.3 pts vs Nifty 500market median 0.0% · five sessions −12.3% (−15.2 pts vs Nifty 500) · volume 4.4× usual · delivery −4.6 pts against usual · The announcement
- 1 Apr 2024Credit ratingdown 0.89%−2.1 pts vs Nifty 500market median 0.0% · five sessions +0.7% (−1.5 pts vs Nifty 500) · volume 0.3× usual · delivery −4.1 pts against usual · The announcement
- 6 Mar 2024Board or managers changeddown 5.64%−5.6 pts vs Nifty 500market median 0.0% · five sessions −19.4% (−15.8 pts vs Nifty 500) · volume 1.2× usual · delivery +0.5 pts against usual · The announcement
- 9 Feb 2024Credit ratingup 3.71%+3.8 pts vs Nifty 500market median 0.0% · five sessions +4.7% (+4.4 pts vs Nifty 500) · volume 2.9× usual · delivery −9.9 pts against usual · The announcement
- 8 Jan 2024Board or managers changeddown 2.14%−1.3 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−1.4 pts vs Nifty 500) · volume 1.2× usual · delivery −13.0 pts against usual · The announcement
- 23 Nov 2023Board or managers changeddown 1.33%−1.4 pts vs Nifty 500market median 0.0% · five sessions +4.3% (+2.2 pts vs Nifty 500) · volume 0.2× usual · delivery +4.4 pts against usual · The announcement
- 7 Nov 2023Board or managers changedup 14.24%+14.1 pts vs Nifty 500market median 0.0% · five sessions +32.4% (+31.2 pts vs Nifty 500) · volume 11.8× usual · delivery −16.5 pts against usual · The announcement
- 26 Sep 2023Board or managers changeddown 0.76%−0.8 pts vs Nifty 500market median 0.0% · five sessions −1.9% (−1.8 pts vs Nifty 500) · volume 0.7× usual · delivery −7.8 pts against usual · The announcement
- 11 May 2023Dividendup 20.00%+19.9 pts vs Nifty 500market median 0.0% · five sessions +33.8% (+34.1 pts vs Nifty 500) · volume 20.1× usual · delivery −14.7 pts against usual · The announcement
- 26 Apr 2023Credit ratingup 4.35%+4.1 pts vs Nifty 500market median 0.0% · five sessions +1.8% (−0.4 pts vs Nifty 500) · volume 0.8× usual · delivery −11.2 pts against usual · The announcement
- 14 Feb 2023Resultsup 13.30%+12.8 pts vs Nifty 500market median −0.7% · five sessions +17.8% (+17.6 pts vs Nifty 500) · volume 15.9× usual · delivery −32.6 pts against usual · The announcement
- 17 Nov 2022Credit ratingdown 1.01%−0.6 pts vs Nifty 500market median 0.0% · five sessions −3.0% (−2.2 pts vs Nifty 500) · volume 0.2× usual · delivery +10.3 pts against usual · The announcement
- 10 Nov 2022Resultsup 20.00%+20.8 pts vs Nifty 500market median −0.7% · five sessions +29.3% (+28.7 pts vs Nifty 500) · volume 11.0× usual · delivery −4.1 pts against usual · The announcement
- 14 Sep 2022Board or managers changedup 0.18%+0.4 pts vs Nifty 500market median 0.0% · five sessions 0.0% (+1.3 pts vs Nifty 500) · volume 0.9× usual · delivery −15.4 pts against usual · The announcement
- 3 Aug 2022Resultsdown 12.04%−12.1 pts vs Nifty 500market median −0.7% · five sessions −17.9% (−18.6 pts vs Nifty 500) · volume 4.3× usual · delivery −5.9 pts against usual · The announcement
- 11 May 2022Dividenddown 12.87%−12.3 pts vs Nifty 500market median 0.0% · five sessions −15.1% (−15.6 pts vs Nifty 500) · volume 5.6× usual · delivery −23.0 pts against usual · The announcement
Neuland Laboratories results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.